{"entity":{"id":"nct04873362","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","aka":["Astefania"],"tldr":"A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.","summary":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy is a phase 3 interventional study registered as NCT04873362 by Hoffmann-La Roche, with 1188 participants enrolled, started 2021-05-04 and due to reach its primary completion in 2027-03-31. Interventions recorded: Atezolizumab, Trastuzumab Emtansine, Placebo and Trastuzumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04873362","url":"https://clinicaltrials.gov/study/NCT04873362"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","her2-positive-early-breast-cancer"],"sections":[],"technologies":["adc","checkpoint-inhibitor","monoclonal-antibody"],"targets":[],"drugs":["atezolizumab","trastuzumab-emtansine","trastuzumab"],"companies":["flatiron-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04873362","phase":"3","setting":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","sponsor":"Hoffmann-La Roche","started":"2021-05-04","startedType":"actual","enrolled":1188,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04873362/","neighbours":{"cancer":[{"id":"her2-positive-early-breast-cancer","kind":"cancer","name":"Early HER2-positive breast cancer","route":"/cancers/her2-positive-early-breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"},{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"}],"company":[{"id":"flatiron-health","kind":"company","name":"Flatiron Health (Roche)","route":"/companies/flatiron-health/"}]}}